Catalent Inc
NYSE:CTLT

Watchlist Manager
Catalent Inc Logo
Catalent Inc
NYSE:CTLT
Watchlist
Price: 63.48 USD Market Closed
Market Cap: 11.5B USD
Have any thoughts about
Catalent Inc?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Catalent Inc

Revenue
4.4B USD
Cost of Revenue
-3.5B USD
Gross Profit
965m USD
Operating Expenses
-1B USD
Operating Income
-48m USD
Other Expenses
-365m USD
Net Income
-413m USD

Margins Comparison
Catalent Inc Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
US
Catalent Inc
NYSE:CTLT
11.5B USD
22%
-1%
-9%
US
Eli Lilly and Co
NYSE:LLY
770.8B USD
81%
38%
24%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
56%
3%
-4%
US
Johnson & Johnson
NYSE:JNJ
391.9B USD
69%
26%
16%
DK
Novo Nordisk A/S
CSE:NOVO B
2.4T DKK
85%
48%
35%
CH
Roche Holding AG
SIX:ROG
243.8B CHF
73%
32%
20%
UK
AstraZeneca PLC
LSE:AZN
186B GBP
82%
23%
13%
US
Merck & Co Inc
NYSE:MRK
239.5B USD
81%
36%
27%
CH
Novartis AG
SIX:NOVN
195.1B CHF
75%
32%
23%
IE
Endo International PLC
LSE:0Y5F
158.2B USD
68%
11%
-126%
US
Pfizer Inc
NYSE:PFE
145.7B USD
74%
25%
13%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Catalent Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Catalent Inc
NYSE:CTLT
11.5B USD
-11%
-4%
-1%
-1%
US
Eli Lilly and Co
NYSE:LLY
770.8B USD
85%
15%
39%
22%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
-2%
2%
2%
US
Johnson & Johnson
NYSE:JNJ
391.9B USD
20%
8%
19%
14%
DK
Novo Nordisk A/S
CSE:NOVO B
2.4T DKK
81%
26%
71%
33%
CH
Roche Holding AG
SIX:ROG
243.8B CHF
40%
13%
29%
22%
UK
AstraZeneca PLC
LSE:AZN
186B GBP
18%
7%
17%
14%
US
Merck & Co Inc
NYSE:MRK
239.5B USD
42%
15%
28%
21%
CH
Novartis AG
SIX:NOVN
195.1B CHF
27%
12%
23%
17%
IE
Endo International PLC
LSE:0Y5F
158.2B USD
70%
-51%
5%
6%
US
Pfizer Inc
NYSE:PFE
145.7B USD
9%
4%
9%
8%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.